Fosfomycine shortage — NL supply status & alternatives | Mederti
Fosfomycine
—
In supply · Australia
In supply · 🇦🇺 Australia · short in🇨🇦 CA🇳🇱 NL
In supply in Australia
Reading today’s signals…
✓ Can I substitute?
Per normal rules
Confirm with prescriber
⇄ Best alternative
None listed
refer to prescriber
◷ Expected back
No estimate
No estimate provided
Product attributes reference data we hold
Active ingredient (INN)
Fosfomycine
Therapeutic category
Auto-created by CBG-MEB (Netherlands) scraper
Controlled substance
No
Patient information leaflet (PIL)
Not on file
Summary of product characteristics (SPC)
Not on file
Trade price 🇦🇺 Australia · awaiting price ingest
🇦🇺 AU
Ex-manufacturer
—
Dispensed (DPMQ)
—
Pack
—
$
Not yet captured for Australia
Official pricing isn’t on file for this market yet. PBS (Australia), NHS Drug Tariff (United Kingdom) and CMS NADAC (United States) feeds are prioritised; this panel populates automatically once the data lands.
Other markets
🇮🇹 IT
€6.51
Retail price
🇫🇷 FR
€4.70
Retail price
🇪🇸 ES
€4.73
Retail price
Substitution pathways 🇦🇺 Australia · TGA
—
No substitution instrument in force
Dispense per normal rules, or refer to the prescriber. No active SSSI/S19A instrument detected for this medicine.
Generated 1 July 2026 · Australia market · 2 regulatory sources
For health-professional reference only. Mederti aggregates shortage and substitution information from official regulatory sources. It is not clinical advice and data may be incomplete or delayed. Confirm any substitution or supply decision against the primary regulator source, the prescriber, and current clinical references (e.g. AMH) before acting. Terms.